Mirabegron Tablet, Extended Release
Product Images NDC 70771-1753

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Mirabegron (NDC 70771-1753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (9dd396b5 4841 483a B63b 63a0e3cea1ae 01)

FDA Label Image

Figure 1 (9dd396b5 4841 483a B63b 63a0e3cea1ae 02)

FDA Label Image

Figure 2 (9dd396b5 4841 483a B63b 63a0e3cea1ae 03)

FDA Label Image

Figure 3 (9dd396b5 4841 483a B63b 63a0e3cea1ae 04)

FDA Label Image

Figure 4 (9dd396b5 4841 483a B63b 63a0e3cea1ae 05)

FDA Label Image

Figure 5 (9dd396b5 4841 483a B63b 63a0e3cea1ae 06)

FDA Label Image

Figure 6 (9dd396b5 4841 483a B63b 63a0e3cea1ae 07)

FDA Label Image

Figure 7 (9dd396b5 4841 483a B63b 63a0e3cea1ae 08)

This text contains data related to mean changes from baseline measurements. The measurements range from 0.00 to -2.00, with various increments in between. There are also references to weeks and different treatments, including a placebo and a drug called mirobegron. It seems to be a comparison between the effects of different doses or treatments on a specific parameter.*

FDA Label Image

Figure 8 (9dd396b5 4841 483a B63b 63a0e3cea1ae 09)

FDA Label Image

Mirabegron Extended-release Tablets, 25mg (9dd396b5 4841 483a B63b 63a0e3cea1ae 10)

FDA Label Image

Mirabegron Extended-release Tablets, 50mg (9dd396b5 4841 483a B63b 63a0e3cea1ae 11)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.